Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

NCT06245824 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan (T-DXd) with pyrotinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences